Edition:
India

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

3.87USD
15 Jan 2019
Change (% chg)

-- (--)
Prev Close
$3.87
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,060,972
52-wk High
$33.60
52-wk Low
$3.15

Latest Key Developments (Source: Significant Developments)

Akorn Says FDA Cites Several Violations In Decatur Facility Warning Letter
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Akorn Inc ::AKORN - FDA, IN DECATUR FACILITY WARNING LETTER, SAYS OBSERVED SPECIFIC VIOLATIONS REGARDING "POOR ASEPTIC BEHAVIOR", "NON-INTEGRAL CLEANROOM MATERIALS".AKORN - FDA, IN DECATUR FACILITY WARNING LETTER, SAYS OBSERVED SPECIFIC VIOLATIONS REGARDING "INADEQUATE CLEANROOM DESIGN & SMOKE STUDY DEFICIENCIES".AKORN - AS PER FDA, CO FAILED TO FOLLOW APPROPRIATE WRITTEN PROCEDURES AT DECATUR FACILITY TO PREVENT MICROBIOLOGICAL CONTAMINATION OF DRUG PRODUCTS.AKORN - FDA, IN DECATUR FACILITY WARNING LETTER, SAYS OBSERVED SPECIFIC VIOLATIONS REGARDING "ENVIRONMENTAL AND PERSONNEL MONITORING" & CLEANING OPERATIONS.AKORN - AS PER FDA, CO FAILED TO FOLLOW A WRITTEN TESTING PROGRAM DESIGNED TO ASSESS THE STABILITY CHARACTERISTICS OF DRUG PRODUCTS AT DECATUR FACILITY.  Full Article

Akorn Receives FDA Warning Letter
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Akorn Inc ::AKORN RECEIVES FDA WARNING LETTER.AKORN INC - WILL RESPOND TO FDA LETTER WITHIN REQUIRED 15 WORKING DAYS.AKORN - RECEIVED WARNING LETTER FROM U.S. FDA RELATED TO AN INSPECTION OF ITS DECATUR, ILLINOIS MANUFACTURING FACILITY IN APRIL AND MAY OF 2018.AKORN INC - EXPECTS TO CONTINUE PRODUCTION AT DECATUR PLANT.  Full Article

Akorn Appoints Douglas Boothe As President And CEO
Friday, 21 Dec 2018 

Dec 20 (Reuters) - Akorn Inc ::AKORN NAMES DOUGLAS S. BOOTHE AS PRESIDENT AND CEO.AKORN INC - DOUGLAS S. BOOTHE HAS BEEN NAMED PRESIDENT AND CHIEF EXECUTIVE OFFICER EFFECTIVE JANUARY 1, 2019.AKORN INC - ANNOUNCED THAT DOUGLAS S. BOOTHE HAS BEEN NAMED PRESIDENT AND CHIEF EXECUTIVE OFFICER EFFECTIVE JANUARY 1, 2019.AKORN INC - MOST RECENTLY, BOOTHE SERVED AS PRESIDENT OF $600 MILLION GENERICS DIVISION OF PUBLICLY HELD IMPAX LABORATORIES.  Full Article

Akorn Q3 Gaap Loss Per Share $0.56
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Akorn Inc ::AKORN PROVIDES THIRD QUARTER 2018 RESULTS.Q3 GAAP LOSS PER SHARE $0.56.Q3 REVENUE $165.6 MILLION VERSUS I/B/E/S VIEW $184.2 MILLION.Q3 EARNINGS PER SHARE VIEW $0.11 -- THOMSON REUTERS I/B/E/S.Q3 ADJUSTED NON-GAAP LOSS PER SHARE $0.06 INCLUDING ITEMS.  Full Article

Akorn Appeals Fresenius Kabi Ruling
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - Akorn Inc ::AKORN APPEALS FRESENIUS KABI RULING.HAS ALSO FILED A MOTION SEEKING EXPEDITED PROCEEDINGS IN ITS APPEAL."DISAGREES WITH OPINION ISSUED OCTOBER 1 BY COURT OF CHANCERY".  Full Article

Akorn Comments On Delaware Chancery Court Ruling
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Akorn Inc ::AKORN COMMENTS ON DELAWARE CHANCERY COURT RULING.AKORN INC - "CONTINUE TO BELIEVE FRESENIUS' ATTEMPT TO TERMINATE TRANSACTION IS IN BREACH OF OUR BINDING MERGER AGREEMENT".AKORN INC - "INTEND TO APPEAL, IN AN EFFORT TO VIGOROUSLY ENFORCE OUR RIGHTS".  Full Article

Fresenius CEO Expects Akorn Matter To Be Resolved By Early 2019
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Fresenius Se ::CEO SAYS ARE CONVINCED OF MERITS OF CASE TO TERMINATE AKORN DEAL.CEO SAYS EVEN IF COURT DOES NOT AGREE IT WAS THE RIGHT DECISION TO TERMINATE DEAL.CEO SAYS EXPECTS AKORN MATTER TO BE FINALLY RESOLVED BY EARLY NEXT YEAR.CFO SAYS LESS LIKELY TO REACH UPPER END OF 2018 SALES GUIDANCE OF 5-8 PERCENT.CEO SAYS IF WE ARE FORCED TO CLOSE AKORN DEAL, WILL NEED TO DO SOME PRETTY SUBSTANTIAL REMEDIATION REGARDLESS OF HOW FDA RESPONDS.  Full Article

Akorn Issues Statement In Response To Fresenius Seeking To Terminate Merger
Monday, 23 Apr 2018 

April 22 (Reuters) - Akorn Inc ::AKORN INC ISSUES STATEMENT IN RESPONSE TO FRESENIUS KABI’S ANNOUNCEMENT THAT IT IS SEEKING TO TERMINATE THE DEFINITIVE MERGER AGREEMENT.AKORN SAYS PREVIOUSLY DISCLOSED ONGOING INVESTIGATION HAS NOT FOUND ANY FACTS THAT WOULD RESULT IN ADVERSE EFFECT ON CO'S BUSINESS.AKORN SAYS SINCE INVESTIGATION DID NOT FIND ANY FACTS RESULTING IN ADVERSE EFFECT ON CO'S BUSINESS, IT IS "NO BASIS TO TERMINATE THE TRANSACTION".AKORN SAYS INTEND TO "VIGOROUSLY" ENFORCE CO'S RIGHTS, AND FRESENIUS’ OBLIGATIONS, UNDER BINDING MERGER AGREEMENT.  Full Article

Fresenius SE & Co. KGaA Fresenius Terminates Merger Agreement With Akorn
Sunday, 22 Apr 2018 

April 22 (Reuters) - Fresenius SE & Co KGaA ::DGAP-ADHOC: FRESENIUS SE & CO. KGAA: FRESENIUS TERMINATES MERGER AGREEMENT WITH AKORN.  Full Article

SEC Says Akorn Inc Agrees To Settle To Reporting, Accounting Control Violations
Monday, 26 Mar 2018 

March 26 (Reuters) - Akorn Inc ::SEC SAYS AKORN INC AND ITS FORMER CFO AND CONTROLLER AGREE TO SETTLE TO REPORTING AND ACCOUNTING CONTROL VIOLATIONS.SEC - AKORN INC, FORMER CFO & CONTROLLER AGREED TO SETTLE THE CHARGES WITHOUT ADMITTING OR DENYING THE COMMISSION'S ALLEGATIONS.  Full Article

Akorn gets FDA warning letter for Illinois plant, shares drop

Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.